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Asymmetric dimethylarginine and 
vascular homeostasis
Methylarginines are formed when arginine residues in 
proteins are methylated by the action of protein arginine 
methyltransferases, and free methylarginines are liberated 
aft er proteolysis. Asymmetric dimethylarginine (ADMA) 
and monomethyl arginine (L-NMMA) are endogenously 
produced amino acids that inhibit all three isoforms of nitric 
oxide synthase. ADMA accumulates in various disease 
states, including renal failure, diabetes, and pulmonary 
hypertension, and its concentration in plasma is strongly 
predictive of premature cardiovascular disease and death. Both 
L-NMMA and ADMA are eliminated largely through active 
metabolism by dimethylarginine dimethylaminohydrolase 
(DDAH); thus DDAH dysfunction may be a crucial unifying 
feature of increased cardiovascular risk. However, despite 
considerable interest in this pathway and in the role of ADMA 
as a cardiovascular risk factor, there is little evidence to 
support a causal role of ADMA in pathophysiology. To test the 
hypothesis that accumulation of endogenous ADMA alters 
vascular function, Leiper et al. inhibited its metabolism to 
citrulline. Th ey fi rst analyzed the structure of human DDAH-1 
(see Figure) and inhibited ADMA metabolism by generating 
mice with targeted deletion of the DDAH1 gene and by 
using DDAH-specifi c inhibitors, which, as demonstrated by 
crystallography, bind to the active site of human DDAH-1. 
Th ey found that loss of DDAH-1 activity led to accumulation 
of ADMA and reduction in nitric oxide signaling. Th is, in 
turn, caused vascular abnormalities, including endothelial 
dysfunction, increased systemic vascular resistance, and 
elevated systemic and pulmonary blood pressures. Th ese 
results add strong support to the long-held suspicion that 
ADMA accumulation has a pathogenic eff ect on vascular 
function and suggest that DDAH modifi cation could be 
harnessed therapeutically. (Nat Med 2007; 13: 198–203)
Juan Oliver
Transcription activation in 
epithelial–mesenchymal transition
Th e mechanisms governing epithelial–mesenchymal transition 
(EMT) are poorly understood. Fibrogenesis following 
organ infl ammation or during wound healing depends on 
the formation and proliferation of new fi broblasts by EMT. 
Previous work by Neilson’s laboratory described a gene 
encoding fi broblast-specifi c protein 1 (FSP1) that activates 
in epithelia during EMT. FSP1, also known as S100A4 in 
the cancer literature, is an intracellular calcium-binding 
protein constitutively and selectively present in newly formed 
fi broblasts. Its appearance is linked to EMT, tissue fi brosis, 
pulmonary vascular disease, increased tumor-cell motility and 
invasiveness, and metastatic tumor development. FSP1 helps 
epithelia transition to new morphology and motility on the 
basis of its ability to infl uence levels of intracellular calcium 
and actin disassembly. Th e important role of FSP1 in EMT is 
underscored by the fi ndings that induction of EMT in vitro by 
epithelial growth factor and transforming growth factor-β is 
blocked by antisense oligomers against mRNA encoding FSP1. 
Several transcription factors appear to activate EMT in various 
settings, including Snail, Twist, high mobility group A2, Slug, 
and erythroblastosis-1 (Ets-1), but understanding of the 
transcription factor control of EMT is far from complete.
In previous work, using promoter deletion constructs 
for FSP1, a novel cis-acting element in the FSP1 promoter 
called fi broblast transcription site-1 (FTS-1) was identifi ed. 
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Cartoon representation of the human DDAH-1 structure.
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Proposed role for CBF-A. αSMA, α-smooth muscle actin; CBF-A, CArG 
box-binding factor-A; EMT, epithelial–mesenchymal transition; Ets-1, 
erythroblastosis-1; FGF-2, fibroblast growth factor-2; FSP1, fibroblast-
specific protein 1; FTS-1, fibroblast transcription site-1; HMGA2, high 
mobility group A2; ILK, integrin-linked kinase; LEF-1, lymphoid enhancer-
binding factor 1; KAP-1, KRAB-associated protein 1; TGFβ, transforming 
growth factor-β; ZO-1, zonula occludens-1.
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Now, in studies using mass spectrometry, chromatin 
immunoprecipitation, and small interfering RNA, Venkov 
et al. have used FTS-1 as a probe for mediators of EMT 
and identifi ed a complex of two proteins, CArG box-
binding factor-A (CBF-A) and KRAB-associated protein 1 
(KAP-1), that bind this site. Epithelial cells engineered to 
conditionally express recombinant CBF-A (rCBF-A) activated 
the transcription of FSP1 and underwent EMT. Th e authors 
also found that the FTS-1 response element also exists in 
the promoters modulating a broader EMT transcriptome, 
including Twist and Snail, as well as E-cadherin, β-catenin, ZO-
1, vimentin, α1(I) collagen, and α-smooth muscle actin, and that 
the induction of rCBF-A appropriately altered their expression 
as well. Hence, these results suggest that formation of the CBF-
A/KAP-1/FTS-1 complex is suffi  cient for the induction of FSP1 
and a novel proximal activator of EMT (see Figure). (J Clin 
Invest 2007; 117: 482–491)
Juan Oliver
Hypoxia-inducible transcription 
factors in polycystic kidney disease
Patients with adult polycystic kidney disease (PKD) are 
frequently less anemic than patients with other types of kidney 
disease and, occasionally, even develop polycythemia. In 
addition, they have high levels of serum erythropoietin (EPO). 
Cyst fl uids have been found to have high concentrations of 
EPO, and stromal cells in the cyst walls express EPO mRNA. 
An additional feature of polycystic kidneys is the increased 
vessel formation in the cyst walls, which was found to be 
associated with enhanced expression of vascular endothelial 
growth factor (VEGF) and its receptors. Th ese fi ndings led to 
the hypothesis that angiogenesis is an important factor in the 
progression of cystic kidney disease, in contrast to most kidney 
diseases, which are usually characterized by rarefi cation of 
peritubular capillaries.
EPO and several angiogenic factors are regulated by 
hypoxia-inducible transcription factors (HIFs). HIF is a 
heterodimer consisting of a constitutive β-subunit (HIF-β) and 
one of two alternative, oxygen-dependent α-subunits (HIF-1α 
and -2α). Th e production of HIF-α is primarily independent 
of oxygen, but HIF degradation is regulated by oxygen 
availability. In the presence 
of molecular oxygen, the 
α-chains are rapidly degraded 
via the ubiquitin–proteasome 
pathway. In hypoxia, HIF-α 
accumulates in the cell and 
forms a heterodimer with HIF-β, 
which binds to a specifi c DNA 
sequence, the hypoxia response 
element. More than 100 HIF 
target genes have been identifi ed 
to date, the vast majority of 
which improve oxygen delivery 
or hypoxia tolerance, including 
genes involved in angiogenesis, 
genes promoting anaerobic 
glucose utilization, and genes 
enhancing systemic oxygen 
transport (for example, EPO). 
Bernhardt et al. hypothesized 
that renal cyst expansion may 
result in pericystic hypoxia and 
consecutive upregulation of HIF. 
Th ey examined the expression 
of HIF-α and HIF target genes 
in human PKD (see Figure) 
and in a rodent PKD model. 
HIF-1α and HIF-2α were found 
to be upregulated in cyst epithelium and cells of cyst walls, 
respectively. Th e distinct expression pattern of the HIF-α 
isoforms closely resembled their respective pattern in normal 
kidneys under systemic hypoxia. Pimonidazole staining, a 
marker for tissue hypoxia, confi rmed the existence of regional 
hypoxia in polycystic kidneys. Immunohistochemistry for 
selected target genes implicated a role for HIF-1α in VEGF 
and Glut-1 activation, and for HIF-2α in endoglin and EPO 
stimulation. Polycystin-defi cient cells showed physiological, 
oxygen-dependent HIF-α modulation, excluding a direct 
infl uence of polycystin defi ciency on HIF-α regulation. In 
conclusion, HIF accumulation in human and rat PKD seems 
to be responsible for increased EPO production and pericystic 
hypervascularity, which may have an impact on progression of 
PKD. (Am J Pathol 2007; 170: 830–842)
Juan Oliver
Expression of HIF target genes 
in adult PKD (ADPKD). HO-1, 
heme oxygenase.
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